Crossmark

Adis summary of research: Lebrikizumab improves quality of life and patient-reported symptoms of anxiety and depression in patients with moderate-to-severe atopic dermatitis

Crossref DOI link: https://doi.org/10.1007/s40267-024-01132-2

Published Online: 2025-02-11

Published Print: 2025-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Blair, Hannah A.
License Information

Text and Data Mining valid from 2025-02-01

Version of Record valid from 2025-02-01
More Information

Article History

Accepted: 4 December 2024

First Online: 11 February 2025

Declarations

:

: The preparation of this review was not supported by any external funding.

: Hannah A. Blair is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

: Not applicable.

Document is current

Any future updates will be listed below